A Pipeline Powered by Passion

A Pipeline Powered by Passion

Pipeline

We're advancing muscle-directed potential treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue.

Cardiovascular
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Omecamtiv Mecarbil
Cardiac Myosin Activator
HFrEF
Aficamten
Cardiac Myosin Inhibitor
oHCM
Aficamten
Cardiac Myosin Inhibitor
oHCM (First Line*)
Aficamten
Cardiac Myosin Inhibitor
Pediatric oHCM
Aficamten
Cardiac Myosin Inhibitor
nHCM
CK-136
Cardiac Troponin Activator
Heart failure, other
CK-586
Cardiac Myosin Inhibitor
HFpEF
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3

Neuromuscular

Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Additional skeletal muscle activators
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3

Other

Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Approved
Medicines
Muscle biology-directed research
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Approved

Cardiovascular

Omecamtiv Mecarbil
Cardiac Myosin Activator; HFrEF
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Aficamten
Cardiac Myosin Inhibitor; oHCM
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Aficamten
Cardiac Myosin Inhibitor; oHCM (First Line*)
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Aficamten
Cardiac Myosin Inhibitor; Pediatric oHCM
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Aficamten
Cardiac Myosin Inhibitor; nHCM
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
CK-136
Cardiac Troponin Activator; Heart failure, other
Research
Pre-Clinical
Phase 1
CK-586
Cardiac Myosin Inhibitor; HFpEF
Research
Pre-Clinical
Phase 1

Neuromuscular

Additional skeletal muscle activators
Research
Pre-Clinical

Other

Muscle biology-directed research
Research

All drug candidates are investigational and are not approved by any regulatory agency. Their safety and effectiveness have not been established.

*Pending results from MAPLE-HCM, an ongoing Phase 3 clinical trial evaluating for the potential superiority of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM.